logo-loader
viewLexagene Holdings Inc.

LexaGene Holdings files patent application to scale-up its LX Analyzer pathogen detection technology

The technology is fully automated and ideally suited to to look for coronavirus in emergency departments and physician practices to help facilitate their medical decisions in one hour or less

Viruses on a blue background
LexaGene has seen demand for the technology from moderate to high-volume testing facilities, including centralized reference labs and large food production operations

LexaGene Holdings Inc (OTCQB:LXXGF) (CVE:LXG) said it has filed a provisional patent application with the US Patent and Trademark Office for expanding the testing capabilities of its pathogen-detecting LX Analyzer technology, which includes coronavirus (COVID-19) and other clinical lab testing. 

The company plans to launch its flagship LX Analyzer in the third quarter with an eye on decentralized testing facilities in the clinical, veterinary, and food safety markets.

The group said the technology is fully automated and ideally suited to look for coronavirus in emergency departments and physician practices to help facilitate their medical decisions in one hour or less, the company said.

“Filing this new patent application is a significant step in expanding the capabilities of our technology, allowing us to meet the challenges of the high-throughput sample testing market,” CEO Jack Regan said in a statement.

“Infectious disease testing is currently in high demand due to the COVID-19 pandemic, and with this filing, LexaGene is positioning itself to provide solutions both at point-of-need and at high-throughput reference laboratories," he added.

READ: LexaGene hires seasoned executive as director of product marketing to help launch LX Analyzer

LexaGene has seen demand for the technology from moderate to high-volume testing facilities, including centralized reference labs and large food production operations. LexaGene’s original design is scalable but doesn’t easily meet the scope of high-volume testers.

To assuage those concerns, the company has filed a new provisional patent application covering a novel design of a fully integrated disposable cartridge that combines high-throughput sample processing with the company’s open-access multiplexing capabilities.

“This new cartridge will allow a tester to process multiple samples simultaneously and will also allow them to test for a multitude of genetic targets using disposable components,” LexaGene's CEO said.

“We expect the simple workflow, ease of use, and reduced waste offered by our new technology will facilitate easy adoption to ease the burden of testing laboratories. Innovation is the cornerstone of our technology, and this new filing will expand our intellectual property portfolio to protect new technologies that are under development.”

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Lexagene Holdings Inc.

Price: 0.93 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $83.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc. named herein, including the promotion by the Company of Lexagene Holdings Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: LexaGene hits milestone by having pre-commercial device in...

LexaGene (CVE: LXG- OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company now has one of their devices that tests for COVID-19 and other respiratory pathogens being used at the Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire. Regan...

on 28/5/20

2 min read